AgarwalaSS, KirkwoodJM. 1994. Interferons in the therapy of solid tumors. Oncology, 51,6:129–136.
2.
DeiningerM, BuchdungerE, DrukerBJ. 2005. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood, 105,7:2640–2653.
3.
GolombHM. 2011. Fifty years of hairy cell leukemia treatments. Leuk Lymphoma, 52,Suppl 2:3–5.
4.
GuttermanJU. 1994. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A, 91,4:1198–1205.
5.
The Italian Cooperative Study Group on Chronic Myeloid Leukemia. 1994. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med, 330,12:820–825.
6.
KantarjianHM, TalpazM, GilesF, O'BrienS, CortesJ. 2006. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med, 145,12:913–923.
7.
MauroMJ, O'DwyerM, HeinrichMC, DrukerBJ. 2002. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol, 20,1:325–334.
8.
ParmarS, PlataniasLC. 2003. Interferons: mechanisms of action and clinical applications. Curr Opin Oncol, 15,6:431–439.
9.
PestkaS, LangerJA, ZoonKC, SamuelCE. 1987. Interferons and their actions. Annu Rev Biochem, 56:727–777.
10.
PlataniasLC, RatainMJ. 1991. Hairy cell leukemia: the role of alpha-interferon. Eur J Cancer, 27,Suppl 4:S53–S57.
